Abstract Library

#4151 Identifying potential tumor drivers through integration of gene expression and DNA copy number in SI-NET

Introduction: The genetics of small intestine neuroendocrine tumors (SI-NETs) remains poorly understood. To date, only CDKN1B has been found recurrently mutated, in approximately 9% of cases. On the contrary, DNA copy number alterations are found in a majority of cases. The most frequent aberration is heterozygous loss of chromosome 18. In addition, loss of chromosome 11, and gains on chromosomes 4, 5 and 14 are common. The cellular mechanisms through which these alterations drive tumor development are unknown.

Conference:

Presenting Author: Backman S

Authors: Backman S, Barazeghi E, Norlén O, Hellman P, Stålberg P,

Keywords: SI-NET, RNA-Seq, Gene dosage, Haplo-insufficiency, Copy number,

#4103 The evolutionary history of metastatic pancreatic neuroendocrine tumors reveals a therapy driven route to high-grade transformation

Introduction: Tumor evolution with acquisition of more aggressive disease characteristics is a hallmark of disseminated cancer. Metastatic pancreatic neuroendocrine tumors (PanNETs) in particular, show frequent progression from a low/intermediate to a high-grade disease.

Conference:

Presenting Author: Crona J

Authors: Backman S, Botling J, Nord H, Ghosal S, Stålberg P,

Keywords: Pancreatic neuroendocrine tumor, Tumor evolution, Alkylating chemotherapy, Treatment resistance,

#4036 Metformin inhibits small intestinal neuroendocrine tumor proliferation in vivo

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are rare and slow-growing, with most patients being diagnosed at a late stage with distant metastases. Metformin has been hypothesized as a potential anti-tumor agent by several studies in the past few years. This has been further confirmed by experimental studies in which metformin has inhibited cancer cell growth in different cancers, and we recently demonstrated that metformin treatment repressed the cell viability of SI-NET cells and inhibited the proliferation of cell spheroids.

Conference:

Presenting Author:

Authors: Axling F, Hellman P, Norlén O, Stålberg P, Barazeghi E,

Keywords: neuroendocrine neoplasm, SI-NET, in vivo model, metformin, RNA-seq, miRNA-seq, xenograft,

#3630 Metformin suppresses small intestinal neuroendocrine tumor growth in vivo

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are rare and slow growing, but most patients are diagnosed at a late stage with distance metastases. In the past few years, several studies have reported the anti-tumor activity of metformin in different cancers, and recently we showed that metformin treatment repressed cell viability of SI-NET cells and inhibited the growth of GOT1 spheroids.

Conference:

Presenting Author:

Authors: Barazeghi E, Axling F, Hellman P, Norlén O, Stålberg P,

Keywords: neuroendocrine tumor, metformin, SI-NET xenograft,

#1645 A Role of TETs and 5-Hydroxymethylcytosine in SI-NETs

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are rare and slow growing neoplasms. Identification of patients with worse outcome and of novel potential targets for therapy is important goals. The epigenetic mark 5-hydroxymethylcytosine (5-hmC) is severely reduced in various cancers and was recently found by us to discriminate between parathyroid adenoma and carcinoma. A growth regulatory role of TET1 was also found.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Barazeghi E, Prabhawa S, Hellman P, Norlén O, Stålberg P,

Keywords: SI-NET, 5-hydroxymethylcytosine, TETs,